Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 + mFOLFOX6(-1) + bevacizumab versus mFOLFOX6 + bevacizumab as first-line treatment for advanced colorectal cancer
CTR20262467Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in colorectal adenocarcinoma, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Aug 2026; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20262467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262467.